ANZUP Mini ASM 2021
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic…
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics…
SCS AUA 2024, prostate cancer, 18F-PSMA-11 PET, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET).
Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial’s analysis of…
Alicia Morgans speaks with Neal Shore about managing biochemical recurrence (BCR) in high-risk patients, particularly following radiotherapy (RT) and radical prostatectomy (RP). Discussing findings from…
SCS AUA 2024, non-muscle invasive bladder cancer (NMIBC), Urothelial Carcinoma of the Prostate, Urothelial Carcinoma of the Prostate and Intravesical Therapy, papillary only disease, bladder…
inguinal hernia, Urinary Continence, Robot-Assisted Radical Prostatectomy, Radical Prostatectomy, inguinal hernia and Urinary Continence.
SCS AUA 2024 real-world treatments following BCG induction in patients with non muscle invasive bladder cancer (NMIBC), Intravesical BCG,
Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner…
Ashish Kamat hosts Paolo Gontero and Michael Cookson to discuss managing high-risk bladder cancer with variant histology. They address the challenges of treating these cases,…